Page 24 - Cognos News Today : Breaking News, Live Updates & Top Stories | Vimarsana

An Ottawa-based startup working on treatments that use the body’s immune system to target cancer, COVID-19 and other diseases has landed millions of dollars in financing to ratchet up its research efforts. Orion Biotechnology’s new series-A round worth US$11.5 million is being led by Keiretsu Forum, a global syndicate of angel investors headquartered in San Francisco.  The new funding will help the firm expand its clinical trials of drug candidates produced by its proprietary platform that targets G-protein coupled receptors, or GPCRs, which play a key role in diseases such as cancer, HI...

Fusion5 bolsters its CPM play as Cortell Australia targets the New Zealand market

Business Scoop provides news and views on Business and Markets from New Zealand

Nel Botha, the co-founder of Cortell New Zealand (rebranded as Mindfull in 2014), a leading business intelligence consultancy, has gone full circle to rejoin the team. Established in 1998, Cortell quickly built up an impressive portfolio of new corporate ...

Cognos Therapeutics Corp. Engages Maxim Group LLC for Investment Banking and Financial Advisory Services June 01, 2021 15:49 ET | Source: Cognos Therapeutics Corp. Cognos Therapeutics Corp. Inglewood, California, UNITED STATES INGLEWOOD, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Cognos Therapeutics Corp. (“Cognos”, the Company”), an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases, announces today that it has signed a Letter of...